LOW COST, RELIABLE, HIGH EFFICIENCY, FUNCTIONAL CELL

低成本、可靠、高效、功能性电池

• 批准号: 2307409
• 负责人: FLOYD E TAUB
• 金额: $ 10万
• 依托单位: SYNCHROCELL, INC./DOVETAIL TECH, INC. JV
• 依托单位国家: 美国
• 财政年份: 1995
• 资助国家: 美国
• 起止时间: 1995-09-30 至
• 项目状态: 未结题
• 来源: https://reporter.nih.gov/project-details/2307409
• 关键词: LOW; COST; RELIABLE; EFFICIENCY; FUNCTIONAL

A renewable source of DNA from patients and family members is needed to evaluate the genetic component of many diseases including IDDM and NIDDM. In the past cells have been transformed in order to immortalize them and provide a continual source of DNA. This procedure is time consuming, expensive and difficult -- thus it makes studies of large populations impractical. In addition, transformation converts normal cells to genetically altered cell lines. This contract is to develop new methods to allow normal cells to be grown in a renewable fashion. This will provide a functionally limitless supply of normal DNA more representative of the starting population of cells. The methods will be easy, reliable, and inexpensive. They utilize the addition of novel small organic molecules to standard culture media. Some of these molecules have already been demonstrated to allow very large numbers of population doublings. Although senescence does eventually occur it takes so long that there is virtually an inexhaustable number of cells. In order to determine the best molecule, Phase I will compare the ability of several unique molecules to increase the population doublings that fibroblasts and lymphocytes undergo in vitro.

需要患者和家人的DNA的可再生能源 评估包括IDDM和NIDDM在内的许多疾病的遗传成分。 在过去 提供持续的DNA来源。此过程很耗时， 昂贵且困难 - 因此使大量人口进行研究 不切实际。另外，转化将正常细胞转换为 基因改变的细胞系。 该合同是要开发新方法以允许正常细胞生长 以可再生的方式。这将提供功能无限的供应 正常DNA的细胞开始群体更具代表性。 这些方法将很容易，可靠且便宜。他们利用了 在标准培养基中添加新型的小有机分子。一些 这些分子已经被证明很大 人口加倍数量。虽然衰老最终确实 发生了这么长时间，几乎没有一个不足的数字 细胞。为了确定最佳分子，I阶段将比较 几个独特分子增加种群的能力 双重成纤维细胞和淋巴细胞的双倍体外。